Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter basket study of 177Lu-DOTATOC in SSTR-positive tumors
2023-000086-14Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177-edotreotide in apudoma (NET) and Nonhematologic neoplasms, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Jan 2023; status: active.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
apudoma (NET)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-000086-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000086-14.